Rare Disease Drugs Turning Huge Profits Catch Congress’ Eye

January 29, 2020

Drug companies developing medications for extremely rare diseases could lose their longer exclusivity period if they later turn a profit under changes to the drug approval process Congress is set to debate.

Related Stories